Our data on the potential additive effects with cytotoxic therapies such as gemcitabine suggest that STING agonists should additionally be tested in combination with tumor-damaging radiation or standard-of-care chemotherapeutic agents to improve the treatment efficacy of patients with pancreatic adenocarcinoma. Here, STING1 is linked to pancreatic adenocarcinoma.